Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis

A Prospective Cohort Study of Patients With Actinic Keratosis (AK) in the Face or Scalp Treated With Tirbanibulin and Followed for 24 Weeks Post Treatment-initiation. Patient Reported Outcomes (PROs) and Clinical Profile of Patients Will be Gathered for Descriptive Analyses of Patient Outcomes Over the 24-week Study Observation Period

The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).

Inclusion Criteria:

• Diagnosed with AK of the face or scalp
• Has clinically typical, visible, and discrete AK lesions
• Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK
• Willing to avoid excessive sun or ultraviolet (UV) exposure, and/or use relevant sunscreen protection and protective clothing during the study duration
• Able to read and write English
• Provide consent to participate in the study
• Willing to comply with all study procedures and be available for the duration of the study

Exclusion Criteria:

• Participants with any dermatological condition of the face or scalp that could interfere with the clinical evaluations.
• Hypertrophic AK lesions, open wounds or suspected skin cancers within close proximity of the treatment area.
• Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months.
• Participants unable to comply with the requirements of the study or participants who in the opinion of the study physician should not participate in the study.
• Participants for whom medical chart is inaccessible to physicians to complete baseline data collection.